toxylact

The first professional lActological database in the word

Loperamide oxide (ATC A07DA05) is an oral prodrug of loperamide used as an antipropulsive antidiarrheal; it is converted in vivo to loperamide and shares its peripheral mechanism and efficacy, and although specific lactation data are lacking, its toxico‑lactological profile can be inferred to be similar to loperamide, which is generally considered compatible with breastfeeding when used at standard doses.atcddd.fhi+6

ATC A07DA05 overview

ATC code A07DA05 “Loperamide oxide” belongs to the A07DA antipropulsives subgroup within A07 antidiarrheals, intestinal anti‑inflammatory/anti‑infective agents. The ATC/DDD index assigns a defined daily dose of 5 mg orally for loperamide oxide, reflecting its use in acute diarrhea, distinct from loperamide hydrochloride (A07DA03, DDD 10 mg).atcddd.fhi+3

Pharmacology and mechanism

Loperamide oxide is an inactive or low‑activity prodrug that is reduced in the body to loperamide, a μ‑opioid receptor agonist acting predominantly in the intestinal wall. The active loperamide decreases propulsive peristalsis, increases intestinal transit time, and enhances absorption of fluids and electrolytes, thereby reducing stool frequency and improving consistency without significant central nervous system penetration at therapeutic doses.ncbi.nlm.nih+3

Therapeutic indications

Clinically, loperamide oxide is indicated for acute diarrhea in adults and has been studied as a treatment for chronic diarrhea associated with Crohn’s disease, where it showed safe and effective symptom control. In the Netherlands, it is marketed (for example under the brand Arestal) for oral use in acute diarrhea, with regimens such as 1–2 mg after each unformed stool for up to one week and mean daily doses around 2.7 mg.drugs.ncats

Pharmacokinetics relevant to lactation

After oral administration, loperamide oxide is absorbed and reduced to loperamide, which is highly lipophilic but undergoes extensive first‑pass metabolism and is efficiently extruded from the brain by P‑glycoprotein. As with direct loperamide, systemic exposure at standard doses is low and the drug acts mainly locally in the gut; based on LactMed, only small amounts of loperamide appear in breast milk, and poor infant oral absorption further limits infant exposure.ncbi.nlm.nih+3

Maternal safety and adverse effects

Adverse effects of loperamide oxide reflect those of loperamide and include constipation, abdominal cramps, nausea, flatulence, and occasional dizziness or fatigue at usual doses. Serious cardiac adverse events (for example arrhythmias) have been associated with high‑dose loperamide abuse rather than therapeutic antidiarrheal dosing, but this underscores the need to respect labeled dose limits.ncbi.nlm.nih+3

Lactation safety assessment

There are no dedicated lactation studies of loperamide oxide, but because its clinical effect depends on in vivo conversion to loperamide, lactation safety is generally extrapolated from loperamide data. LactMed and breastfeeding guidelines state that standard‑dose loperamide use by breastfeeding women is unlikely to affect the infant, and infant exposure is minimal due to low maternal plasma levels and poor infant oral absorption, supporting a low‑risk classification for loperamide‑based therapy.ncbi.nlm.nih+4

Potential effects on the breastfed infant

Given the low expected milk levels of loperamide after conversion from loperamide oxide and the limited infant bioavailability, clinically relevant opioid‑like effects (sedation, respiratory depression) in healthy, full‑term breastfed infants are not anticipated at standard antidiarrheal doses. As with loperamide, caregivers should watch for changes in infant feeding, unusual constipation, or excessive sleepiness, especially in younger or medically fragile infants, though such events are considered unlikely.pmc.ncbi.nlm.nih+3

Practical recommendations in breastfeeding

For breastfeeding mothers with acute diarrhea, non‑pharmacological management (oral rehydration, continued breastfeeding) remains first‑line, with loperamide (direct or via loperamide oxide) considered an acceptable symptomatic therapy when indicated. In the absence of specific human milk data for loperamide oxide, clinicians should preferentially use standard loperamide, which is better characterized in lactation, but if loperamide oxide is the available formulation, it can be used short‑term at labeled doses with documentation and routine infant observation.medicalguidelines.msf+6

Role among antipropulsives

Within the A07DA antipropulsives class, loperamide oxide functions pharmacologically as a prodrug version of loperamide and shares its favorable peripheral selectivity and efficacy profile, contrasting with centrally acting opioids such as diphenoxylate, difenoxin, and opium preparations that pose higher lactation risks. From a toxico‑lactological standpoint, it belongs to the low‑risk subgroup of antidiarrheals appropriate for breastfeeding women, provided dosing is short‑term, within recommended limits, and integrated with optimal rehydration.atcddd.fhi+5

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.